Dara-CyBorD for New Multiple Myeloma with Kidney Failure
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Just been diagnosed with multiple myeloma
- Have kidney problems (low kidney function or need dialysis)
- Able to do daily activities with little or no help (ECOG score 2 or less)
- Not allergic to any of the study medicines
- No serious heart, lung, or nerve conditions
- Not pregnant, breastfeeding, or planning pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial is for people with multiple myeloma who have already completed 12 cycles of a standard treatment (daratumumab, lenalidomide, and dexamethasone) and are doing well. It tests whether taking a break from treatment is safe and effective, instead of continuing without a break.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.